Company Overview and News

14
Achaogen: Smaller Label, Unchanged Market?

1h seekingalpha
Last Thursday, Achaogen (AKAO) organized a lunch with two KOLs and analysts to inform the investment community on how the company is preparing for the commercialization of its recently approved antibiotic Zemdri.
AKAO

28
Superbugs Win Another Round as Big Pharma Leaves Antibiotics - Bloomberg

2018-07-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AZN PRTK MDCO MTFB MLNT ACT GSK RHHBF MTFBF RHHVF AGN AGN.PRA RHHBY NVS GSK AKAO

40
10 Strong Buy Stocks for Under $10 | InvestorPlace

2018-07-12 investorplace
Just because a stock is cheap doesn’t mean you should have to compromise on quality. These 10 Strong Buy stocks tick all the boxes. True, they are all trading for under $10, but they also represent compelling investing opportunities based on far more than just their price. I used TipRanks’ stock screener to purposefully scan for stocks with a Strong Buy consensus rating from analysts and top analysts alike.
RIGL GSM LC MCRB NYTAB AKAO RESN GLUU GNMK CLF

25
Rounds Report: The July 4th Weekend Procured Substantial Profits For Investors As Solid BioSciences Continued Its Rally

2018-07-12 seekingalpha
The overall bioscience market concluded the July 4th weekend with all sort of fireworks. Many equities under our coverage continued to procure further gains for investors.
CDTX SLDB PRTK FTSV MLNT IBB AKAO TTOO XBI

16
Achaogen to Host Investor Lunch Updating Investors on Commercial Strategy Post FDA Approval of Plazomicin on July 12th in New York City

2018-07-10 globenewswire
― Key opinion leaders Steven Burdette, M.D., (Professor of Medicine at Wright State University Boonshoft School of Medicine) and Joshua Rosenberg, M.D. (Chair of Critical Care at The Brooklyn Hospital Center) to present and provide perspectives ―
AKAO

17
Achaogen: Zemdri To The Rescue

2018-07-10 seekingalpha
I hitched a recent ride on Achaogen in hopes that it would rise from its downdraft.
BSI AKAO AP CRL

19
AKAO / Achaogen, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-07-10 sec.gov
SCHEDULE 13G Amendment No. 5 ACHAOGEN INC COMMON STOCK Cusip #004449104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #004449104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 80,192 Item 6: 0 Item 7: 1,673,395 Item 8: 0 Item 9: 1,673,395 Item 11: 3.735% Item 12: HC Cusip #004449104 Item 1: Reporting Person - Abigail P.
AKAO

23
AKAO / Achaogen, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-07-10 sec.gov
SCHEDULE 13G Amendment No. 5 ACHAOGEN INC COMMON STOCK Cusip #004449104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #004449104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 80,192 Item 6: 0 Item 7: 1,673,395 Item 8: 0 Item 9: 1,673,395 Item 11: 3.735% Item 12: HC Cusip #004449104 Item 1: Reporting Person - Abigail P.
AKAO

132
Gogo, Real Goods Solar Topple into Monday’s 52-Week Low Club

2018-07-09 247wallst
July 9, 2018: Here are four stocks trading with heavy volume among 33 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by about 1.74 to 1 and on the Nasdaq, advancers led decliners by about 1.66 to 1.
RGSE GOGO AKAO

20
Is There Any Chance For New Antibiotics?

2018-07-06 seekingalpha
All developers of new antibiotics are in the doghouse, whether their drugs have been launched, approved, are waiting for approval or still have trials to do.
AKAO

57
Achaogen: Falling Knife Or Major Bargain?

2018-06-28 seekingalpha
Small cap antibiotic concern Achaogen have fallen ~25% in trading since Tuesday after a mixed FDA decision around its primary drug candidate.
AKAO

88
Your Daily Pharma Scoop: Glaukos And Achaogen Approvals, Puma Up On EU Prospects, FOLD Down

2018-06-28 seekingalpha
Readers note: The Analysis Focus section is now only available to TPT subscribers. This follows the announcement from yesterday.
ACHV GKOS PBYI FOLD AKAO PTIE

58
Rounds Report: Spectrum To Potentially Enter Into A Merger & Acquisition

2018-06-28 seekingalpha
The overall bioscience market traded with a mixed sentiment for the day. Nevertheless, many equities under our coverage continued to post further gains.
SPPI JEF IBB AKAO XBI

68
Biotech Analysis Central Pharma News: Puma's Reversal Win, Pain Therapeutics Suffers Major Blow, Achaogen's FDA Score

2018-06-27 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
PBYI AKAO PTIE

AKAO : Achaogen Stock Analysis and Research Report

2017-11-08 - Asif

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant (“MDR”) gram-negative infections. Achaogen is researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (“cUTI”), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action” and in 2017 the World Health Organization identified CRE as a Global Priority 1 Pathogen: Critical Need for Research and Development of New Antibiotics. On December 12, 2016, the company announced positive data from its two Phase 3 clinical trials for plazomicin. The firs...

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

1h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

CUSIP: 004449104